Berberine: metabolic and cardiovascular effects in preclinical and clinical trials

References

• Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29(10):1316–1326.
   Web of Science ®Google Scholar
• Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26(1):13–24.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1K–34K.
   PubMed Web of Science ®Google Scholar
• Sénécal M, Fodor G, Gagné C, et al. Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational. Curr Med Res Opin. 2009;25(1):47–55.
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83(6):687–700.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab. 2008;1(2):85–93.
   Google Scholar
• Birdsall TC, Kelly GS. Berberine: Therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev. 1997;2:94–103.
   Google Scholar
• Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. The involvement of p-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002;91:193–197.
   PubMedGoogle Scholar
• Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos. 2003;32:405–412.
   Web of Science ®Google Scholar
• Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos. 2006;34:2064–2072.
   PubMed Web of Science ®Google Scholar
• Chen CM, Chang HC. Determination of berberine in plasma, urine and bile by high performance liquid chromatograpy. J Chromatogr. 1995;665:117–123.
   Web of Science ®Google Scholar
• Raner GM, Cornelious S, Moulick K, Wang Y, Mortenson A, Chech NB. Effects of herbal products on human cytochrome P450(2E1) activity. Food Chem Tox. 2007;45:2359–2365.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang JJ, Wang X, Bu XY, Lou YQ, Zhang GL. Effect of berberine on hepatocyte proliferation inducible nitric oxide synthase expression, cyrochrome 450 2E1 and 1A2 activities in diethylnitrosamine- and Phenobarbital-treated rats. Biomed Pharmacother. 2008;62:567–572.
   PubMed Web of Science ®Google Scholar
• Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal regulated kinase – dependent stabilization of hepatic low density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25:2170–2176.
   PubMed Web of Science ®Google Scholar
• Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine induced LDLR up-regulation involves JNK pathway. Biochem Biophy Res Commun. 2007;362:853–857.
   PubMed Web of Science ®Google Scholar
• Choi BH, Ahn IS, Kim YH, et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3L1 adipocyte. Exp Mol Med. 2006;38:599–605.
   PubMed Web of Science ®Google Scholar
• Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47: 1281–1288.
   PubMed Web of Science ®Google Scholar
• Jia X, Chen Y, Zidichousky J, Zhang J, Sun C, WangY. Co-administration of berberine and plant sterols synergistically reduces plasma cholesterol in rats. Atherosclerosis. 2009;201(1):101–107.
   Web of Science ®Google Scholar
• Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008;57:1029–1037.
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–1351.
   PubMed Web of Science ®Google Scholar
• Zhang Y, LI X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93:2559–2565.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterollowering agents. A single-blind clinical investigation. Arzneimittelforschung. 2007;57:26–30.
   PubMed Web of Science ®Google Scholar
• Kong WJ, Zhang H, Song DQ, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2009;58:109–119.
   PubMed Web of Science ®Google Scholar
• Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005;28:1431–1437.
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu YC, Guo FJ, Meng Y, Li ML. Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J 2008;121:2124–2128.
   Google Scholar
• Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443.
   PubMed Web of Science ®Google Scholar
• Lu SS, Yu YL, Zhu HJ, et al. Berberne promotes glucagons like peptide-1(7–36 amide) secretion in streptozocin-induced diabetic rats. J Endocrinol. 2009;200(2):159–165.
   Google Scholar
• Wang ZQ, Lu FE, Leng SH, et al. Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity. World J Gastroenterol. 2008;14:6004–6011.
   PubMed Web of Science ®Google Scholar
• Leng S, Lu F, Xu L. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004;25:496–502.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang X, Shao L, et al. Berberine acutely inhibits insulin secretion from beta-cells through 3’,5’-cyclic adenosine 5’-monophosphate signaling pathway. Endocrinology. 2008;149(9):4510–4518.
   Web of Science ®Google Scholar
• Zhou J, Zhou S, Tang J, et al. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol. 2009;606(1–3):262–268.
   Web of Science ®Google Scholar
• Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57:1414–1418.
   PubMed Web of Science ®Google Scholar
• Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. PhytotherRes. 2008;22:999–1012.
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2008;8:99–111.
   PubMedGoogle Scholar
• Yi P, Lu FE, Xu LJ, Chen G, Dong H, Wang KF. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol. 2008;14:876–883.
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin EJ, Kim ED, Bayaraa T, Frost SC, Hyun CK. Berberine activated GLUT-1 -mediated glucose uptake in 3T3-L1 adipocytes. Bio Pharm Bull. 2007;30:2120–2125.
   PubMed Web of Science ®Google Scholar
• Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294:E148–E156.
   PubMed Web of Science ®Google Scholar
• Zhou L, Yang Y, Wang X, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism. 2007;56: 405–412.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Pang T, Gu M, et al. Berberine stimulated glucose uptake in L6 myotubes includes both AMPK and p 38 MAPK. Biochim Biophys Acta. 2006;1760:1682–1689.
   PubMed Web of Science ®Google Scholar
• Zhou JY, Zhou SW, Zhang KB, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull. 2008;31(6): 1169–1176.
   PubMed Web of Science ®Google Scholar
• Huang C, Zhang Y, Gong Z, et al. Berberine inhibits 3T3L1 adipocyte differentiation through the PPARgamma pathway. Biochem BiophysRes Comun. 2006;348:571–578.
   PubMed Web of Science ®Google Scholar
• Wang SH, Wang WJ, Wang XF, Chen W. Effects of Astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004;24:926–928.
   PubMedGoogle Scholar
• Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–717.
   PubMed Web of Science ®Google Scholar
• Fatehi-Hassanabad Z, Zafarzadeh M, Tarhini A, Fatehi M. The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res. 2005; 19: 222–225.
   PubMed Web of Science ®Google Scholar
• Peychev L. Pharmacological investigation on the cardiovascular effects of Berberine vulgaris on tested animals. Pharmacia. 2005;52:118–121.
   Google Scholar
• Chun YT, Yip TT, Lu KL, Kong YC, Sankawa U. A biochemical study on hypotensive effects of berberine in rats. Gen Pharmacol. 1979;10:177–182.
   PubMedGoogle Scholar
• Wong KK. Mechanism of the aortic relaxation induced by low concentrations of berberine. Planta Med. 1998;64:756–757.
   PubMed Web of Science ®Google Scholar
• Ko WH, Yao XQ, Lau CW, et al. Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol. 2000;399:187–196.
   PubMed Web of Science ®Google Scholar
• Kang DG, Sohn EJ, Kwon EK, Han JH, Oh H, Lee HS. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vasc Pharmacol. 2003;39:281–286.
   Web of Science ®Google Scholar
• Olmez E, Ilhan M. Evaluation of the alpha-adrenoceptor antagonistic action of berberine in isolated organs. Arzneimittelforschung. 1992; 42:1095–1097.
   PubMed Web of Science ®Google Scholar
• Chiou WE, Yen MH, Chen CF. Mechanism of vasodilatory effect of berberine in rat mesenteric artery. Eur J Pharmacol. 1991;204:35–40.
   PubMed Web of Science ®Google Scholar
• Pan LR, Tang Q, Fu Q, Hu BR, Xiang JZ, Qian JQ. Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin. 2005;26:1334–1338.
   PubMed Web of Science ®Google Scholar
• Kang DG, Sohn EJ, Kwon EK, Han JH, Oh H, Lee HS. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascul Pharmacol. 2002;39:281–286.
   PubMed Web of Science ®Google Scholar
• Ko WH, Yao XO, Lau CW, et al. Vasorelaxant and antiproliferative effects of berberine. Eur J Pharmacol. 2000;399:187–196.
   PubMed Web of Science ®Google Scholar
• Wong KK. Mechanism of the aortic relaxation induced by low concentrations of berberine. Planta Med. 1998;64:756–757.
   PubMed Web of Science ®Google Scholar
• Liu WH, Hei ZQ, Nie H, et al. Berberine ameliorates renal injury in streptozocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J. 2008;121:706–712.
   PubMed Web of Science ®Google Scholar
• Liang KW, Yin SC, Ting CT, et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK- dependent pathway in vascular smooth muscle cells. Eur J Pharmacol. 2008;590:343–354.
   PubMed Web of Science ®Google Scholar
• Liu W, Tang F, Deng Y, et al. Berberine reduces fibronectin and collagen accumulation in rat glomerular mesengial cells cultured under high glucose condition. Mol CellBoichem. 2009;325(1–2):99–105.
   Web of Science ®Google Scholar
• Liang KW, Ting CT, Yin SC, et al. Berberine suppresses MEK/ERK-dependent Egr-1 signalling pathway and inhibits vascular smooth muscle regrowth after in vitro mechanical injury. Biochem Pharmacol. 2006;71:806–817.
   PubMed Web of Science ®Google Scholar
• Cho BJ, Im EK, Kwon JH, et al. Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1,2 pathway in smooth muscle cells. Mol Cells. 2005;20: 429–34.
   PubMed Web of Science ®Google Scholar
• Xu MG, Wang JM, Chen L, Wang Y, Yang Z, Tao J. Berberine-induced upregulation of endothelial progenitor cells in related to nitric oxide production in healthy subjects. Cardiology. 2008;112:279–286.
   PubMed Web of Science ®Google Scholar
• Xu MG, Wang JM, Chen L, Wang Y, Yang Z, Tao J. Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens. 2008;22:389–393.
   PubMed Web of Science ®Google Scholar
• Hong Y, Hui SS, Chan BT, Hou J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 2003; 72:2499–2507.
   PubMed Web of Science ®Google Scholar
• Hong Y, Hui SC, Chan TY, Hou JY. Effect of berberine on regression of pressure overload induced cardiac hypertrophy in rats. Am J Chin Med. 2002;30:589–599.
   PubMed Web of Science ®Google Scholar
• Huang WM, Yan H, Lin JM, Yu C, Zhang H. Beneficial effects of berberine on hemodynamics during acute ischemic left ventricular failure in dogs. Chin Med J. 1992;105:1014–1019.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen SG, Ju HS, et al. Mechanisms of protective effects of berberine on ischemia/reperfusion injury in isolated rat heart. Methods Find Exp Clin Pharmacol. 1992;14:677–684.
   PubMedGoogle Scholar
• Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK and HERG channels of cardiac myocytes. Acta Pharmacol Sin. 2001;22:125–131.
   PubMed Web of Science ®Google Scholar
• Wang YX, Zheng YM. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine. J Cardiovasc Pharmacol. 1997;30:214–222.
   PubMed Web of Science ®Google Scholar
• Wang YX, Yao XJ, Tan YH. Effects of berberine on delayed after depolarisations in ventricular muscles in vitro and in vivo. J Cardiovasc Pharmacol. 1994;23;716–722.
   Google Scholar
• Wang YX, Zheng YM, Zhou XB. Inhibitory effects of berberine on ATP-sensitive K+ channels in cardiac myocytes. Eur J Pharmacol. 1996;316:307–315.
   PubMed Web of Science ®Google Scholar
• Huang Z, Chen S, Zhang G, et al. Protective effects of berberine and phentolamine on myocardial reoxygenation damage. Chin Med Sci. 1992;7:221–225.
   Google Scholar
• Marin-Neto JA, Maciel BC, Secches AL, Gallo Junior L. Cardiovascular effects of berberine in patints with severe congestive heart failure. Clin Cardiol. 1988;11:253–260.
   PubMed Web of Science ®Google Scholar
• Zeng XH, LI YY. Clinical observations of the effect of berberine for congestive heart failure. US Chin J Angiocardiomyopathy. 2001;6:308–311.
   Google Scholar
• Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev. 2001;19:234–244.
   PubMed Web of Science ®Google Scholar
• Huang HL, Chu ZL, Wei SJ, Jiang H, Jiao BH. Effects of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. Thromb Res. 2002;106;223–227.
   Google Scholar
• Huang CG, Chu ZL, Yang ZM. The progress in pharmacological researches on berberine. Comun Inform Pharm. 1991;9:10–12.
   Google Scholar
• Holy EW, Akhmedov A, Lüscher TF, Tanner FC. Berberine a natural lipid-lowering drug, exerts prothrombic effects on vascular cells. J Mol Cell Cardiol. 2009;46(2):234–240.
   Web of Science ®Google Scholar
• Guo Y, Wang QZ, Li FM, Jiang X, Zuo YF, Wang L. Biochemical pathways in the antiatherosclerotic effect of berberine. Chin Med J. 2008;121:1197–1203.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008;68:5370–5379.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim Y, Kim JE, Cho KH, Chung JH. Berberine inhibits TPA- induced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine. 2008;15:340–347.
   PubMed Web of Science ®Google Scholar
• Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK, Do MS. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3L1 adipocyte. Exp Mol Med. 2006;38:599–605.
   PubMed Web of Science ®Google Scholar
• Chen FL, Yang ZH, Liu Y, et al. Berberine inhibits the expression of TNF-alpha, MCP-1 and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine. 2008;33(3):331–337.
   Web of Science ®Google Scholar
• Tan Y, Tang Q, Hu BR, Xiang JZ. Antioxidant properties of berberine on cultured rabbit corpus cavernosum smooth muscle cells injured by hydrogen peroxide. Acta Pharmacol Sin. 2007;28:1914–1918.
   Web of Science ®Google Scholar
• Hsieh YS, Kuo WH, Lin TW, et al. Perotective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized-LDL induced cytotoxicity on endothelial cells. J Agric Food Chem. 2007;55:10473–10445.
   Web of Science ®Google Scholar
• Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, Wang H. Protection by and anti-oxidant mechanisms of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol. 2008;35:303–309.
   Web of Science ®Google Scholar
• Hwang JM, Wang CJ, Chou FP, et al. Inhibitory effect of berberine on tert-butyl- hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol. 2002;76:664–670.
   PubMed Web of Science ®Google Scholar
• Sabir M, Bhide NK. Study of some pharmacological actions of berberine. Indian J Physiol Pharmacol. 1971;15:111–132.
   PubMedGoogle Scholar
• Kupeli E, Kosar M, Yesilada E, Husnu K, Baser C. A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish berberis species. Life Sci. 2002;72:645–657.
   PubMed Web of Science ®Google Scholar
• Yuan J, Shen XZ, Zhu XS. Effect of berberine on transit time of human small intestine. Zhongguo ZhongXi Yi Jie He Za Zhi. 1994;14: 718–720.
   PubMedGoogle Scholar
• Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonat. 1993;63;201–208.
   Google Scholar
• Tan YZ, Wu AC, Tan BY, et al. Study on the interactions of berberine displace other drug from their plasma proteins binding sites. Chin Pharmacol Bull. 2002;18:576–578.
   Google Scholar
• Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28:25–29.
   PubMed Web of Science ®Google Scholar
• Wu X, Lu Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporine A in renal transplanted recipients:clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61:567–572.
   PubMed Web of Science ®Google Scholar
• Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008;376(6):449–461.
   Web of Science ®Google Scholar
• Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of the digestive tract cancers to Paclitaxel. Br J Cancer. 1999;81:416–422.
   PubMed Web of Science ®Google Scholar
• Vrzal R, Zdarilova A, Ulrichova J, Blaha L, Giesy JP, Dvorak Z. Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIEcells: Biphasic effect on CYP1A1. Biochem Pharmacol. 2005;70:925–936.
   PubMed Web of Science ®Google Scholar